

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail, bearing Express Mail No. EL923479227US mail in an envelope addressed to: BOX PATENT APPLICATION Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Margaret Pierce		
Signature		Date	November 8, 2001

<b>PRELIMINARY AMENDMENT</b>		Attorney Docket Confirmation No.	UCAL107DIV
Address to: Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231		First Named Inventor	A. Bistrup
		Application Number	(unassigned)
		Filing Date	(herewith)
		Group Art Unit	(unassigned)
		Examiner Name	(unassigned)
		Title	Glycosyl sulfotransferase-3

Sir:

Prior to examination of the application on the merits, please enter the following amendments:

### I. AMENDMENTS

#### IN THE SPECIFICATION

Please replace the paragraph beginning on page 1, line 4, with the following rewritten paragraph:

This application is a divisional application of U.S. Patent Application Serial No. 09/190,911, filed November 12, 1998, which is a continuation-in-part of application serial no. 09/045,284, filed on March 20, 1998, the disclosures of which are incorporated by reference herein.

#### IN THE CLAIMS

Cancel claims 1-15, 21, and 25-29 without prejudice to renewal.

Please enter the amendments to claims 16, 18, and 23, as shown below.

Please enter new claims 30-41, as shown below.

16. (Amended) A method for inhibiting a binding event between a selectin and a selectin ligand, said method comprising:

contacting a cell that produces said selectin ligand with an agent that inhibits the sulfation activity of a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3), KSGal6ST, and homologs thereof.

18. (Amended) A method of inhibiting a selectin mediated binding event in a mammalian

host, said method comprising:

administering to said host an effective amount of a pharmaceutical composition comprising an active agent that modulates the sulfation activity of a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3) and KSGal6ST and homologues thereof.

19. (Amended) The method according to Claim 18, wherein said active agent inhibits the sulfation activity of said glycosyl sulfotransferase.

23. (Amended) A method of modulating a symptom in a mammalian host of a disease condition associated with a selectin mediated binding event, said method comprising:

administering to said host a pharmaceutical composition comprising an effective amount of an active agent that modulates the sulfation activity of a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3) and KSGal6ST and homologues thereof.

-- 30. (New) The method of claim 16, wherein the GST-3 is encoded by a nucleic acid having a sequence that is at least 75% identical to SEQ ID NO:2.

31. (New) The method of claim 16, wherein the selectin ligand is selected from the group consisting of an L-selectin ligand, a P-selectin ligand, and an E-selectin ligand.

32. (New) The method of claim 16, wherein the selectin is an L-selectin, and the selectin ligand is an L-selectin ligand.

33. (New) The method of claim 19, wherein the agent is an antibody specific for GST-3.

34. (New) The method of claim 19, wherein the agent is a small molecule.

35. (New) The method of claim 18, wherein the GST-3 is encoded by a nucleic acid having a sequence that is at least 75% identical to SEQ ID NO:2.

36. (New) The method of claim 23, wherein said disease condition is selected from the group

consisting of inflammation, rheumatoid arthritis, Sjogren's syndrome, Hashimoto's disease, Grave's disease, diabetes, ulcerative colitis, dermatitis, inflammation-associated or allergic reaction patterns of the skin, atopic dermatitis, infantile eczema, contact dermatitis, psoriasis lichen planus, and tissue rejection during transplantation.

37. (New) The method of claim 23, wherein the disease condition is tissue rejection.
38. (New) The method of claim 23, wherein the disease condition is bronchial asthma.
39. (New) The method of claim 23, wherein the disease condition is rheumatoid arthritis.
40. (New) The method of claim 23, wherein the disease condition is diabetes.
41. (New) The method of claim 24, wherein the inflammation is skin inflammation. --

## I. REMARKS

### Formal Matters

Claims 16-20, 22-24, and 30-35 are pending after entry of the amendments set forth herein.

Claims 16, 18, and 23 are amended. Support for the amendments to claim 16 is found in the claims as originally filed, and throughout the specification, including at the following exemplary locations: page 28, lines 20-22; page 9, line 25 to page 10, line 6; page 28, lines 22-25; and page 50, line 20 to page 51, line 10. The amendments to claims 18, and 23 are merely editorial in nature.

Accordingly, no new matter is added.

Please replace claims 16, 18, and 23 with the clean version provided above.

New claims 30-41 are added. Support for new claims 30-35 is found in the claims as originally filed, and throughout the specification, in particular at the following exemplary locations: claims 30 and 35: page 13, lines 8-10; claim 31: page 28, lines 17-18; claim 32: page 28, lines 18-19; claim 33: page 29, line 12 to page 32, line 19; claim 34: page 28, lines 25-27; and page 29, lines 1-11; and claims 36-41: page 37, lines 7-27.

Claims 1-15, 21, and 25-29 are canceled without prejudice to renewal, without intent to acquiesce to any rejection, and without intent to surrender any subject matter encompassed by the canceled claims. Applicants expressly reserve the right to pursue any canceled subject matter in one or more continuation and/or divisional applications.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Applicants respectfully request entry of the above amendments to the specification and claims.

## III. CONCLUSION

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Atty Dkt. No.: UCAL107DIV

USSN: (unassigned)

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number UCAL107DIV.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: Nov. 8, 2001

By:

  
Paula A. Borden  
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

F:\DOCUMENT\UCAL\107div\Prelim Amend.doc

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Please enter the following amendments.

**IN THE SPECIFICATION**

This application is a divisional application of U.S. Patent Application Serial No. 09/190,911, filed November 12, 1998, which is a continuation-in-part of application serial no. 09/045,284, filed on March 20, 1998, the [disclosure] disclosures of which [is] are incorporated by reference herein.

**IN THE CLAIMS**

Please enter the amendments to claims 16, 18, 19, and 23, as shown below.

16. (Amended) A method for inhibiting a binding event between a selectin and a selectin ligand, said method comprising:

contacting [said selectin with a non-sulfated selectin ligand,] a cell that produces said selectin ligand with [glycosyl sulfotransferase-3 and] an agent that inhibits the sulfation activity of [said] a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3), KSGal6ST, and homologs thereof.

18. (Amended) A method of inhibiting a selectin mediated binding event in a mammalian host, said method comprising:

administering to said host an effective amount of a pharmaceutical composition comprising an active agent that modulates the sulfation activity of a [sulfatase] sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3) [GST-3] and KSGal6ST and homologues thereof.

19. (Amended) The method according to Claim 18, wherein said active agent inhibits the sulfation [of] activity of said glycosyl sulfotransferase.

23. (Amended) A method of modulating a symptom in a mammalian host of a disease condition associated with a selectin mediated binding event, said method comprising:

administering to said host a pharmaceutical composition comprising an effective amount of an active agent that modulates the sulfation activity of a [sulfatase] sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3) [GST-3] and KSGal6ST and homologues thereof.